MY182429A - Compositions relating to a mutant clostridium difficile toxin and methods thereof - Google Patents
Compositions relating to a mutant clostridium difficile toxin and methods thereofInfo
- Publication number
- MY182429A MY182429A MYPI2017001631A MYPI2017001631A MY182429A MY 182429 A MY182429 A MY 182429A MY PI2017001631 A MYPI2017001631 A MY PI2017001631A MY PI2017001631 A MYPI2017001631 A MY PI2017001631A MY 182429 A MY182429 A MY 182429A
- Authority
- MY
- Malaysia
- Prior art keywords
- difficile toxin
- clostridium difficile
- mutant
- methods
- relates
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000003053 toxin Substances 0.000 title abstract 4
- 231100000765 toxin Toxicity 0.000 title abstract 4
- 241000193163 Clostridioides difficile Species 0.000 title abstract 3
- 108700012359 toxins Proteins 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 108700022831 Clostridium difficile toxB Proteins 0.000 abstract 1
- 102000005927 Cysteine Proteases Human genes 0.000 abstract 1
- 108010005843 Cysteine Proteases Proteins 0.000 abstract 1
- 102000000340 Glucosyltransferases Human genes 0.000 abstract 1
- 108010055629 Glucosyltransferases Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 abstract 1
- 101710182532 Toxin a Proteins 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478474P | 2011-04-22 | 2011-04-22 | |
| US201161478899P | 2011-04-25 | 2011-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY182429A true MY182429A (en) | 2021-01-25 |
Family
ID=46085103
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017001631A MY182429A (en) | 2011-04-22 | 2012-04-20 | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
| MYPI2013701986A MY168205A (en) | 2011-04-22 | 2012-04-20 | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2013701986A MY168205A (en) | 2011-04-22 | 2012-04-20 | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
Country Status (30)
| Country | Link |
|---|---|
| US (13) | US8481692B2 (enExample) |
| EP (4) | EP4365196A3 (enExample) |
| JP (8) | JP5917682B2 (enExample) |
| KR (1) | KR101667837B1 (enExample) |
| CN (3) | CN111647059B (enExample) |
| AR (1) | AR086199A1 (enExample) |
| AU (6) | AU2012245904B2 (enExample) |
| BR (2) | BR112013027229B1 (enExample) |
| CA (1) | CA2832712C (enExample) |
| CO (1) | CO6801643A2 (enExample) |
| DK (2) | DK3549949T5 (enExample) |
| ES (3) | ES2742823T3 (enExample) |
| FI (1) | FI3549949T3 (enExample) |
| HR (2) | HRP20231631T1 (enExample) |
| HU (2) | HUE065594T2 (enExample) |
| IL (8) | IL270779B2 (enExample) |
| MX (3) | MX391236B (enExample) |
| MY (2) | MY182429A (enExample) |
| NZ (1) | NZ616035A (enExample) |
| PE (2) | PE20181334A1 (enExample) |
| PH (1) | PH12013502178B1 (enExample) |
| PL (3) | PL3549949T3 (enExample) |
| PT (2) | PT2699587T (enExample) |
| RU (2) | RU2592686C2 (enExample) |
| SA (3) | SA115360698B1 (enExample) |
| SG (3) | SG10201911993UA (enExample) |
| SI (3) | SI3549949T1 (enExample) |
| TW (6) | TWI671313B (enExample) |
| WO (1) | WO2012143902A1 (enExample) |
| ZA (1) | ZA201307818B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008014733A1 (de) * | 2006-08-02 | 2008-02-07 | Johannes Gutenberg-Universität Mainz | Arzneimittel gegen lct-vergiftungen |
| CA2745096C (en) * | 2008-12-09 | 2013-11-05 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
| US9598472B2 (en) | 2010-09-03 | 2017-03-21 | Valneva Austria Gmbh | Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof |
| GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| BR112013027229B1 (pt) * | 2011-04-22 | 2020-10-27 | Wyeth Llc | polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante |
| BR112014013876A2 (pt) | 2011-12-08 | 2019-09-24 | Novartis Ag | vacina à base de toxina de clostridium difficile |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| DK3489261T3 (da) | 2012-08-24 | 2020-12-14 | Univ California | Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase |
| US20140081659A1 (en) | 2012-09-17 | 2014-03-20 | Depuy Orthopaedics, Inc. | Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| SG11201502730SA (en) * | 2012-11-06 | 2015-05-28 | Bayer Pharma AG | Formulation for bispecific t-cell engagers (bites) |
| US9493518B2 (en) * | 2013-03-14 | 2016-11-15 | National Health Research Institutes | Compositions and methods for treating clostridium difficile-associated diseases |
| EP4079760A3 (en) | 2013-03-15 | 2023-01-25 | Sanofi Pasteur Inc. | Antibodies against clostridium difficile toxins and methods of using the same |
| EP2988778A4 (en) * | 2013-04-22 | 2016-12-14 | Board Of Regents Of The Univ Of Oklahoma | CLOSTRIDIUM DIFFICILE IMPREGENT AND METHOD OF USE |
| AU2014277981B2 (en) | 2013-06-14 | 2019-06-20 | Sanofi Pasteur Inc. | Compositions and methods of immunizing against C. difficile |
| US9717711B2 (en) | 2014-06-16 | 2017-08-01 | The Lauridsen Group | Methods and compositions for treating Clostridium difficile associated disease |
| HUE038212T2 (hu) * | 2014-07-25 | 2018-10-29 | Biosynth Srl | Többszörös beépített epitópokat kifejezõ molekuláris konstrukt bázikus egységeket tartalmazó glikokonjugátum vakcinák enteropatogén baktériumok által okozott fertõzések elleni szélesspektrumú vakcina elõállításához |
| US11434264B2 (en) * | 2015-02-13 | 2022-09-06 | Quanterix Corporation | Immunoassays for differential detection of clostridium difficile |
| US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
| JP7109007B2 (ja) | 2016-06-27 | 2022-07-29 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | がん治療の組み合わせ |
| US20190211377A1 (en) * | 2016-12-22 | 2019-07-11 | Roche Molecular Systems, Inc. | Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile |
| MX2020003756A (es) * | 2017-09-28 | 2020-07-29 | Pfizer | Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile. |
| WO2020201985A1 (en) * | 2019-04-01 | 2020-10-08 | Pfizer Inc. | Compositions and methods for eliciting an immune response against clostridium difficile |
| WO2020231859A1 (en) * | 2019-05-10 | 2020-11-19 | The Board Of Regents Of The University Of Oklahoma | Clostridioides difficile tcdb variants, vaccines and methods of use |
| WO2020231930A1 (en) * | 2019-05-11 | 2020-11-19 | The Texas A&M University System | Protein inhibitors of clostridium difficile toxin b |
| KR102376876B1 (ko) | 2020-04-09 | 2022-03-21 | 대진대학교 산학협력단 | 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도 |
| EP4146200A4 (en) * | 2020-05-06 | 2024-05-15 | Albert Einstein College of Medicine | AGENTS FOR PREVENTING TISSUE DAMAGE RELATED TO CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITING THE BACTERIAL TOXINS TCDA AND TCDB DAMAGED THE INTESTIN |
| US20230218735A1 (en) | 2020-06-19 | 2023-07-13 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| CN111755068B (zh) * | 2020-06-19 | 2021-02-19 | 深圳吉因加医学检验实验室 | 基于测序数据识别肿瘤纯度和绝对拷贝数的方法及装置 |
| AU2023235562A1 (en) | 2022-03-14 | 2024-08-22 | Pfizer Inc. | Methods for producing an adjuvant |
| US20250213667A1 (en) | 2022-06-01 | 2025-07-03 | Valneva Austria Gmbh | Clostridium difficile vaccine |
| US20240189410A1 (en) | 2022-12-13 | 2024-06-13 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
| EP4658302A1 (en) | 2023-02-02 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| WO2024196707A2 (en) * | 2023-03-17 | 2024-09-26 | The Board Of Trustees Of The University Of Illinois | Chimeric antibody molecules based on tetrameric teleost immunoglobulin m |
| WO2025057058A1 (en) | 2023-09-13 | 2025-03-20 | Pfizer Inc. | Methods for producing an adjuvant |
| WO2025257712A1 (en) * | 2024-06-12 | 2025-12-18 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58216123A (ja) | 1982-06-10 | 1983-12-15 | Kazue Ueno | 抗血清 |
| US4689299A (en) | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
| US4713240A (en) | 1985-04-04 | 1987-12-15 | Research Corporation | Vaccines based on insoluble supports |
| US5358868A (en) | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5919665A (en) | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
| US5599539A (en) | 1989-10-31 | 1997-02-04 | Ophidian Pharmaceuticals, Inc. | Therapy for clostridial botulinum toxin |
| US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| US5578308A (en) | 1990-02-12 | 1996-11-26 | Capiau; Carine | Glutaraldehyde and formalin detoxified bordetella toxin vaccine |
| US5231003A (en) | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
| DE69223955T2 (de) | 1991-04-22 | 1998-08-13 | Massachusetts Health Research Institute, Inc. (Mhri), Boston, Mass. | Verfahren für das screening von plasma-proben für einen effektiven antikörpernachweis gegen respiratorische viren |
| US6221363B1 (en) | 1991-07-11 | 2001-04-24 | Baxter Aktiengesellschaft | Vaccine for the prevention of lyme disease |
| CA2158651C (en) | 1993-03-29 | 2009-09-01 | David S. Roberts | Multicomponent clostridial vaccines using saponin adjuvants |
| MX9701683A (es) | 1994-09-06 | 1997-06-28 | Galagen Inc | Tratamiento terapeutico de enfermedades asociadas a clostridium difficile. |
| JP2002514886A (ja) | 1994-10-24 | 2002-05-21 | プロメガ コーポレーション | クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン |
| US6743430B1 (en) | 1995-03-29 | 2004-06-01 | Richard E. Parizek | Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose |
| US5610023A (en) | 1995-03-31 | 1997-03-11 | Lee Laboratories, Inc. | Method of purification of clostridium difficile toxin A and production of mono-specific antibodies |
| US5919463A (en) | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
| CN1195993A (zh) | 1995-07-07 | 1998-10-14 | 奥拉瓦克斯有限公司 | 抗胃肠疾病的鼻内接种 |
| ATE195878T1 (de) | 1995-07-07 | 2000-09-15 | Oravax Inc | Toxine und toxoide von clostridium difficile als schleimhautadjuvans |
| EP0952773B1 (en) | 1995-09-15 | 2005-11-23 | Dale N. Gerding | Methods and compositions for prevention and treatment of clostridium difficile-associated diseases |
| BR9712091A (pt) | 1996-07-12 | 1999-10-05 | Edwin C Iliff | Sistema computadorizado para diagnóstico clìnico utilizando processamento com base em listagem |
| IL128014A (en) | 1996-09-30 | 2003-11-23 | Univ Arkansas | Method of producing active immunity with vaccine conjugate, a vaccine preparation useful for the production of said vaccine conjugate and a process for the manufacture of said vaccine |
| US20100267012A1 (en) | 1997-11-04 | 2010-10-21 | Bergeron Michel G | Highly conserved genes and their use to generate probes and primers for detection of microorganisms |
| WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US20050106157A1 (en) | 1997-05-27 | 2005-05-19 | Deckers Harm M. | Immunogenic formulations comprising oil bodies |
| EP1000155A1 (en) | 1997-06-20 | 2000-05-17 | QUEEN MARY & WESTFIELD COLLEGE | Immunogenic fragments of toxin a of clostridium difficile |
| DE19739685A1 (de) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
| EP1568378B1 (en) | 1997-10-20 | 2016-03-16 | Sanofi Pasteur Biologics, LLC | Immunization against Clostridium difficile disease |
| DE69829400T2 (de) | 1997-10-20 | 2006-04-13 | Acambis, Inc., Cambridge | Passive immunisierung gegen durch clostridium difficile verursachte krankheit |
| US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| US6733760B1 (en) | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| CA2365914A1 (en) * | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| EP1169456B1 (en) | 1999-04-09 | 2012-07-11 | Intercell USA, Inc. | Recombinant production of Clostridium difficile Toxin A or Toxin B |
| WO2000062800A2 (en) | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| GB0008682D0 (en) | 2000-04-07 | 2000-05-31 | Microbiological Res Authority | Transformation of clostridium difficile |
| MXPA02010826A (es) * | 2000-05-04 | 2006-03-09 | Harvard College | Compuestos y metodos para el tratamiento y la prevencion de infeccion bacteriana. |
| DE60217107T2 (de) * | 2001-06-20 | 2007-08-23 | Ramot At Tel Aviv University Ltd. | Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung |
| US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
| AU2003242024A1 (en) | 2002-06-05 | 2003-12-22 | Chugai Seiyaku Kabushiki Kaisha | Method of constructing antibody |
| WO2004041857A2 (en) * | 2002-06-17 | 2004-05-21 | Ballard Jimmy D | Mutant of clostridium difficile toxin b and methods of use |
| US20040235139A1 (en) | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
| WO2004081515A2 (en) * | 2003-03-13 | 2004-09-23 | Glaxosmithkline Biologicals S.A. | Purification process for bacterial cytolysin |
| US20050020506A1 (en) | 2003-07-25 | 2005-01-27 | Drapeau Susan J. | Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use |
| JP5602336B2 (ja) | 2004-01-16 | 2014-10-08 | フェネックス インコーポレイテッド | シュードモナス・フルオレッセンスにおける哺乳動物タンパク質の発現 |
| NZ530709A (en) | 2004-01-21 | 2006-07-28 | Agres Ltd | Improved IGA production method |
| ES2533492T3 (es) * | 2004-02-06 | 2015-04-10 | University Of Massachusetts | Anticuerpos contra toxinas de Clostridium difficile y usos de los mismos |
| GB0421083D0 (en) * | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
| CA2592015A1 (en) * | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
| WO2006130925A1 (en) | 2005-06-10 | 2006-12-14 | Monash University | Genetic manipulation of clostridium difficile |
| GB0512751D0 (en) | 2005-06-22 | 2005-07-27 | Glaxo Group Ltd | New adjuvant |
| US20080038761A1 (en) * | 2006-01-30 | 2008-02-14 | Invitrogen Corporation | Compositions and methods for detecting and quantifying toxic substances in disease states |
| KR101149687B1 (ko) * | 2006-03-30 | 2012-05-25 | 엠브렉스, 인코포레이티드 | 가금류의 예방접종 방법 및 조성물 |
| CN101500581B (zh) * | 2006-06-08 | 2013-10-30 | 科内尔研究基金会 | 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法 |
| GB0612301D0 (en) | 2006-06-21 | 2006-08-02 | Morvus Technology Ltd | DNA molecules and methods |
| WO2008024769A2 (en) | 2006-08-21 | 2008-02-28 | Raven Biotechnologies, Inc. | Intensified perfusion production method |
| US7775167B2 (en) | 2006-08-22 | 2010-08-17 | Monsanto Technology Llc | Custom planter and method of custom planting |
| SI2124556T1 (sl) | 2006-10-09 | 2015-01-30 | Charleston Laboratories, Inc. | Farmacevtske sestave |
| US9023352B2 (en) * | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
| US8554548B2 (en) * | 2007-03-02 | 2013-10-08 | Panasonic Corporation | Speech decoding apparatus and speech decoding method including high band emphasis processing |
| EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
| US9096638B2 (en) | 2007-09-06 | 2015-08-04 | Geneohm Sciences Canada, Inc. | Detection of toxigenic strains of Clostridium difficile |
| KR20160005378A (ko) * | 2007-09-14 | 2016-01-14 | 사노피 파스테르 바이오로직스, 엘엘씨 | 클로스트리듐 디피실리 톡소이드 ａ 및 ｂ를 포함하는 약학적 조성물 |
| WO2009132082A2 (en) * | 2008-04-22 | 2009-10-29 | Medical College Of Georgia Research Institute, Inc. | Immunogenic compositions containing ceramide and methods of use thereof |
| EP2288719A4 (en) | 2008-05-15 | 2012-01-11 | Univ Tufts | METHOD FOR DIAGNOSIS OF CLOSTRIDIUM DIFFICILE AND METHOD AND VECTORS FOR RECOMBINANT TOXINEXPRESSION |
| JP5712126B2 (ja) | 2008-06-25 | 2015-05-07 | ノバルティス アーゲー | 遅延型追加刺激免疫処置に対する迅速な応答 |
| EP2146490A1 (en) | 2008-07-18 | 2010-01-20 | Alcatel, Lucent | User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems |
| US20120020996A1 (en) | 2008-08-06 | 2012-01-26 | Jonathan Lewis Telfer | Vaccines against clostridium difficile and methods of use |
| EP2329029B1 (en) | 2008-09-24 | 2016-06-08 | Sanofi Pasteur Biologics, LLC | Methods and compositions for increasing toxin production |
| WO2010040000A2 (en) | 2008-10-01 | 2010-04-08 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | A multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia |
| US10369204B2 (en) * | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| WO2010063693A1 (en) | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Vetmedica Gmbh | Process for production of vaccines |
| CA2745096C (en) | 2008-12-09 | 2013-11-05 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
| GB0901001D0 (en) * | 2009-01-22 | 2009-03-04 | Univ Nottingham | Methods |
| AU2010215275B2 (en) * | 2009-02-20 | 2016-03-31 | Micropharm Limited | Antibodies to Clostridium difficile toxins |
| KR20120061053A (ko) | 2009-08-27 | 2012-06-12 | 시냅틱 리서치, 엘엘씨 | 유도 만능 줄기(ｉＰＳ) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템 |
| US10046040B2 (en) * | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
| CA2782406A1 (en) * | 2009-12-02 | 2011-06-09 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
| GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| CN101870978A (zh) * | 2010-03-23 | 2010-10-27 | 王世霞 | 密码子优化的艰难梭菌外毒素a羧基端基因序列及其核酸疫苗 |
| KR20130072201A (ko) | 2010-03-30 | 2013-07-01 | 피페넥스 인크. | 재조합 독소 단백질의 고수준 발현 |
| US8765399B2 (en) | 2010-05-18 | 2014-07-01 | Montefiore Medical Center | Cultures and protocols for diagnosis of toxigenic Clostridium difficile |
| US9598472B2 (en) | 2010-09-03 | 2017-03-21 | Valneva Austria Gmbh | Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof |
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| US9285372B2 (en) * | 2010-11-12 | 2016-03-15 | Reflexion Pharmaceuticals, Inc. | Methods and compositions for identifying D-peptidic compounds that specifically bind target proteins |
| BR112013027229B1 (pt) | 2011-04-22 | 2020-10-27 | Wyeth Llc | polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante |
| DK2714910T3 (en) | 2011-05-27 | 2018-02-05 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2012166991A1 (en) * | 2011-05-31 | 2012-12-06 | The Board Of Regents Of The University Of Texas Systeem | S-nitrosylation of glucosylating toxins and uses therefor |
| BR112014013876A2 (pt) | 2011-12-08 | 2019-09-24 | Novartis Ag | vacina à base de toxina de clostridium difficile |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| AU2013319821A1 (en) | 2012-09-19 | 2015-02-26 | Novartis Ag | Clostridium difficile polypeptides as vaccine |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| AU2013352034B2 (en) | 2012-11-28 | 2018-08-02 | Emergent Biosolutions Canada Inc. | Antibodies against Clostridium difficile |
| CN112807422A (zh) | 2012-12-05 | 2021-05-18 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| GB201223342D0 (en) | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EP4079760A3 (en) | 2013-03-15 | 2023-01-25 | Sanofi Pasteur Inc. | Antibodies against clostridium difficile toxins and methods of using the same |
| CA2907154A1 (en) | 2013-03-15 | 2014-09-18 | Sanofi Pasteur, Inc. | Toxoids, compositions and related methods |
| US20170165375A1 (en) | 2013-04-02 | 2017-06-15 | Stc. Unm | Antibiotic protocells and related pharmaceutical formulations and methods of treatment |
| AU2014277981B2 (en) | 2013-06-14 | 2019-06-20 | Sanofi Pasteur Inc. | Compositions and methods of immunizing against C. difficile |
| WO2015061529A1 (en) | 2013-10-23 | 2015-04-30 | The Rockefeller University | Compositions and methods for prophylaxis and therapy of clostridium difficile infection |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| RU2021135165A (ru) | 2015-11-17 | 2021-12-29 | Пфайзер Инк. | Среды и способы ферментации для производства полисахаридов в бактериальной клеточной культуре |
| CN117244049A (zh) | 2016-02-16 | 2023-12-19 | 哈佛学院院长等 | 病原体疫苗及其生产和使用方法 |
| CA3056090A1 (en) | 2017-03-15 | 2018-09-20 | Novavax, Inc. | Methods and compositions for inducing immune responses against clostridium difficile |
| US10577665B2 (en) | 2017-09-05 | 2020-03-03 | Mcmaster University | Aptamers for clostridium difficile detection |
| MX2020003756A (es) | 2017-09-28 | 2020-07-29 | Pfizer | Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile. |
| JP6704173B2 (ja) | 2019-09-26 | 2020-06-03 | パナソニックＩｐマネジメント株式会社 | 開閉器及び分電盤 |
-
2012
- 2012-04-20 BR BR112013027229-5A patent/BR112013027229B1/pt active IP Right Grant
- 2012-04-20 EP EP23207942.6A patent/EP4365196A3/en active Pending
- 2012-04-20 HR HRP20231631TT patent/HRP20231631T1/hr unknown
- 2012-04-20 HU HUE19167276A patent/HUE065594T2/hu unknown
- 2012-04-20 HU HUE12720966A patent/HUE047085T2/hu unknown
- 2012-04-20 JP JP2014505775A patent/JP5917682B2/ja active Active
- 2012-04-20 SI SI201232051T patent/SI3549949T1/sl unknown
- 2012-04-20 CN CN202010510962.7A patent/CN111647059B/zh active Active
- 2012-04-20 CN CN201280030656.7A patent/CN103619871B/zh active Active
- 2012-04-20 WO PCT/IB2012/051999 patent/WO2012143902A1/en not_active Ceased
- 2012-04-20 MY MYPI2017001631A patent/MY182429A/en unknown
- 2012-04-20 SI SI201232048T patent/SI3505531T1/sl unknown
- 2012-04-20 ES ES12720966T patent/ES2742823T3/es active Active
- 2012-04-20 RU RU2013145170/10A patent/RU2592686C2/ru active
- 2012-04-20 FI FIEP19167276.5T patent/FI3549949T3/fi active
- 2012-04-20 BR BR122019017005-3A patent/BR122019017005B1/pt active IP Right Grant
- 2012-04-20 DK DK19167276.5T patent/DK3549949T5/da active
- 2012-04-20 CA CA2832712A patent/CA2832712C/en active Active
- 2012-04-20 EP EP19151036.1A patent/EP3505531B1/en active Active
- 2012-04-20 TW TW106131031A patent/TWI671313B/zh active
- 2012-04-20 SG SG10201911993UA patent/SG10201911993UA/en unknown
- 2012-04-20 PH PH1/2013/502178A patent/PH12013502178B1/en unknown
- 2012-04-20 PE PE2018000975A patent/PE20181334A1/es unknown
- 2012-04-20 AR ARP120101365A patent/AR086199A1/es active IP Right Grant
- 2012-04-20 PE PE2013002389A patent/PE20141029A1/es active IP Right Grant
- 2012-04-20 MX MX2017014548A patent/MX391236B/es unknown
- 2012-04-20 TW TW108114747A patent/TWI701257B/zh active
- 2012-04-20 US US13/451,631 patent/US8481692B2/en not_active Ceased
- 2012-04-20 CN CN201611125122.9A patent/CN107022532B/zh active Active
- 2012-04-20 ES ES19151036T patent/ES2968629T3/es active Active
- 2012-04-20 KR KR1020137030696A patent/KR101667837B1/ko active Active
- 2012-04-20 TW TW111129989A patent/TWI815599B/zh active
- 2012-04-20 PL PL19167276.5T patent/PL3549949T3/pl unknown
- 2012-04-20 SG SG10201602668VA patent/SG10201602668VA/en unknown
- 2012-04-20 SG SG2013074992A patent/SG194132A1/en unknown
- 2012-04-20 PT PT12720966T patent/PT2699587T/pt unknown
- 2012-04-20 MX MX2017005518A patent/MX385834B/es unknown
- 2012-04-20 DK DK12720966.6T patent/DK2699587T3/da active
- 2012-04-20 NZ NZ616035A patent/NZ616035A/en unknown
- 2012-04-20 MX MX2013012344A patent/MX347521B/es active IP Right Grant
- 2012-04-20 HR HRP20240042TT patent/HRP20240042T1/hr unknown
- 2012-04-20 AU AU2012245904A patent/AU2012245904B2/en active Active
- 2012-04-20 PT PT191672765T patent/PT3549949T/pt unknown
- 2012-04-20 TW TW101114168A patent/TWI650329B/zh active
- 2012-04-20 EP EP12720966.6A patent/EP2699587B1/en active Active
- 2012-04-20 TW TW109107042A patent/TWI804717B/zh active
- 2012-04-20 TW TW108101678A patent/TWI686402B/zh active
- 2012-04-20 ES ES19167276T patent/ES2969952T3/es active Active
- 2012-04-20 MY MYPI2013701986A patent/MY168205A/en unknown
- 2012-04-20 PL PL19151036.1T patent/PL3505531T3/pl unknown
- 2012-04-20 SI SI201231646T patent/SI2699587T1/sl unknown
- 2012-04-20 PL PL12720966T patent/PL2699587T3/pl unknown
- 2012-04-20 IL IL270779A patent/IL270779B2/en unknown
- 2012-04-20 EP EP19167276.5A patent/EP3549949B1/en active Active
- 2012-04-20 RU RU2015154443A patent/RU2754446C2/ru active
- 2012-04-21 SA SA115360698A patent/SA115360698B1/ar unknown
- 2012-04-21 SA SA115360697A patent/SA115360697B1/ar unknown
- 2012-04-21 SA SA112330472A patent/SA112330472B1/ar unknown
-
2013
- 2013-03-22 US US13/848,909 patent/US8557548B2/en not_active Ceased
- 2013-08-19 US US13/970,048 patent/US8900597B2/en not_active Ceased
- 2013-10-17 IL IL228944A patent/IL228944A/en active IP Right Grant
- 2013-10-21 ZA ZA2013/07818A patent/ZA201307818B/en unknown
- 2013-10-24 CO CO13252702A patent/CO6801643A2/es unknown
-
2014
- 2014-10-31 US US14/529,147 patent/US9745354B2/en active Active
-
2015
- 2015-07-10 US US14/796,741 patent/US9187536B1/en not_active Ceased
- 2015-10-14 US US14/883,000 patent/USRE46376E1/en active Active
-
2016
- 2016-01-21 JP JP2016009882A patent/JP6097853B2/ja active Active
- 2016-04-11 IL IL245047A patent/IL245047A0/en active IP Right Grant
- 2016-05-05 AU AU2016202903A patent/AU2016202903B2/en active Active
- 2016-12-01 US US15/366,702 patent/USRE46518E1/en active Active
-
2017
- 2017-02-17 JP JP2017027808A patent/JP6321239B2/ja active Active
- 2017-07-12 US US15/648,092 patent/US10774117B2/en active Active
- 2017-09-07 IL IL254440A patent/IL254440B/en active IP Right Grant
- 2017-09-11 IL IL254418A patent/IL254418B/en active IP Right Grant
- 2017-10-12 JP JP2017198569A patent/JP2018052938A/ja active Pending
- 2017-10-31 IL IL255345A patent/IL255345B/en active IP Right Grant
- 2017-11-13 AU AU2017261465A patent/AU2017261465B2/en active Active
-
2018
- 2018-02-22 AU AU2018201296A patent/AU2018201296A1/en not_active Abandoned
- 2018-04-03 JP JP2018071560A patent/JP6735784B2/ja active Active
- 2018-10-11 JP JP2018192593A patent/JP6892425B2/ja active Active
-
2019
- 2019-03-20 US US16/359,267 patent/US10597428B2/en active Active
- 2019-03-20 IL IL265510A patent/IL265510B/en active IP Right Grant
- 2019-04-18 US US16/387,999 patent/USRE48862E1/en active Active
- 2019-04-18 US US16/388,011 patent/USRE48863E1/en active Active
- 2019-10-11 AU AU2019246878A patent/AU2019246878B2/en active Active
- 2019-12-05 US US16/704,777 patent/US11535652B2/en active Active
-
2020
- 2020-03-11 IL IL273231A patent/IL273231B/en unknown
- 2020-09-08 AU AU2020230248A patent/AU2020230248B2/en active Active
-
2021
- 2021-05-27 JP JP2021088838A patent/JP7097478B2/ja active Active
-
2022
- 2022-06-27 JP JP2022102418A patent/JP2022126822A/ja active Pending
- 2022-12-15 US US18/066,591 patent/US20230391835A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013502178B1 (en) | Compositions relating to a mutant clostridium difficile toxin and methods thereof | |
| MX369289B (es) | Composiciones y metodos relacionados con una toxina mutante de clostridium difficile. | |
| PH12014501410A1 (en) | Compositions and methods for antibodies targeting factor p | |
| WO2012096926A3 (en) | Method for delivering agents into cells using bacterial toxins | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| EP4296361A3 (en) | Immunogenic composition | |
| SG10201405377XA (en) | Compositions and methods for antibodies targeting complement protein c5 | |
| WO2009149200A3 (en) | Compositions and methods comprising variant microbial proteases | |
| WO2010129304A3 (en) | Method for making heteromultimeric molecules | |
| MY156315A (en) | Anti-vegf antibodies | |
| EP3892709A3 (en) | Variants and compositions comprising variants with high stability in presence of a chelating agent | |
| MX350126B (es) | Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo. | |
| NZ703597A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| MX2009004167A (es) | Anticuerpos que enlazan epitopos cxcr7. | |
| BR112015014727B8 (pt) | Composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| IN2014MN01868A (enExample) | ||
| WO2009137778A3 (en) | Methods and compositions for genetically engineering clostridia species | |
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| WO2012142113A3 (en) | Isopeptide bond formation in bacillus species and uses thereof | |
| WO2010011952A3 (en) | Flip death effector domain derived peptides for inducing autophagy | |
| MX2010002773A (es) | Antigenos mutantes de gas57 y anticuerpos de gas57. | |
| NZ702285A (en) | Staphylococcal coagulase antigens and methods of their use | |
| MX365560B (es) | Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes. | |
| AR124505A2 (es) | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus métodos |